Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 618 - 634
Published: June 20, 2023
An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications this are profound. This study aimed develop an aligned, prioritised research agenda for global community.
Language: Английский
Hepatology, Journal Year: 2023, Volume and Issue: 77(4), P. 1335 - 1347
Published: Jan. 3, 2023
Background and Aims: NAFLD is a leading cause of liver-related morbidity mortality. We assessed the global regional prevalence, incidence, mortality using an in-depth meta-analytic approach. Approach Results: PubMed Ovid MEDLINE were searched for population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA). Meta-analysis was conducted random-effects models. Bias risk assessment Joanna Briggs Institute. Of 2585 reviewed, 92 (N=9,361,716) met eligibility criteria. Across study period (1990–2019), pooling prevalence estimates ultrasound-defined yielded overall 30.05% (95% CI: 27.88%–32.32%) 30.69% (28.4–33.09), respectively. Global increased by +50.4% 25.26% (21.59–29.33) in 1990–2006 38.00% (33.71–42.49) 2016–2019 ( p <0.001); +38.7% 25.16% (19.46–31.87) 34.59% (29.05–40.57) =0.029). The highest Latin America 44.37% (30.66%–59.00%), then Middle East North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East (33.07%, 18.99%–51.03%), (31.20%, 25.86%–37.08%), (29.71%, 25.96%–33.76%), Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among cohort diagnosed without liver biopsy, pooled rate 1000 PY 12.60 (6.68–23.67) all-cause mortality; 4.20 (1.34–7.05) cardiac-specific 2.83 (0.78–4.88) extrahepatic cancer-specific 0.92 (0.00–2.21) liver-specific Conclusions: 30% increasing which requires urgent comprehensive strategies raise awareness address all aspects on local, regional, levels.
Language: Английский
Citations
1412
The Lancet, Journal Year: 2022, Volume and Issue: 400(10360), P. 1345 - 1362
Published: Sept. 6, 2022
Language: Английский
Citations
1345
Diabetes Care, Journal Year: 2022, Volume and Issue: 45(11), P. 2753 - 2786
Published: Sept. 23, 2022
The American Diabetes Association and the European for Study of convened a panel to update previous consensus statements on management hyperglycemia in type 2 diabetes adults, published since 2006 last updated 2019. target audience is full spectrum professional health care team providing U.S. Europe. A systematic examination publications 2018 informed new recommendations. These include additional focus social determinants health, system, physical activity behaviors, including sleep. There greater emphasis weight as part holistic approach management. results cardiovascular kidney outcomes trials involving sodium–glucose cotransporter inhibitors glucagon-like peptide 1 receptor agonists, assessment subgroups, inform broader recommendations cardiorenal protection people with at high risk disease. After summary listing recommendations, practical tips implementation are provided.
Language: Английский
Citations
1158
Diabetologia, Journal Year: 2022, Volume and Issue: 65(12), P. 1925 - 1966
Published: Sept. 23, 2022
Language: Английский
Citations
675
Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(6), P. 388 - 398
Published: March 28, 2023
Language: Английский
Citations
375
Cell Metabolism, Journal Year: 2022, Volume and Issue: 34(11), P. 1700 - 1718
Published: Oct. 7, 2022
Language: Английский
Citations
364
Cell Metabolism, Journal Year: 2022, Volume and Issue: 34(7), P. 969 - 977.e2
Published: June 3, 2022
Language: Английский
Citations
342
Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S32 - S42
Published: Dec. 15, 2022
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of worldwide. The estimated global incidence NAFLD 47 cases per 1,000 population and higher among males than females. prevalence adults 32% (40%) compared to females (26%). has increased over time, from 26% in studies 2005 or earlier 38% 2016 beyond. varies substantially by world region, contributed differing rates obesity, genetic socioeconomic factors. exceeds 40% the Americas South-East Asia. projected increase significantly multiple regions 2030 if current trends are left unchecked. In this review, we discuss future projections.
Language: Английский
Citations
328
Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. E93 - E94
Published: Nov. 20, 2023
Lazarus, Jeffrey V.; Newsome, Philip N.; Francque, Sven M.; Kanwal, Fasiha; Terrault, Norah A.; Rinella, Mary E. Author Information
Language: Английский
Citations
296
Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 842 - 852
Published: May 10, 2023
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common globally, currently estimated to affect 38% of global population. A minority patients with NAFLD will progress cirrhosis or hepatocellular carcinoma, but total number this vast population that risk such severe outcomes is increasing. Worryingly, persons are affected by at an earlier age, suggesting they have longer time develop complications. With considerable changes in diet composition and urbanization, obesity type 2 diabetes among population, particular developing countries, proportion projected be further Yet, there large geographical discrepancies prevalence rates its inflammatory component non-alcoholic steatohepatitis (NASH). Such differences partly related differing socio-economic milieus, also genetic predisposition.This narrative review discusses recent epidemiology NASH from regional perspectives, as well special populations. We discuss consequences these can on hepatic extra-hepatic events.
Language: Английский
Citations
287